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tion on hospital care was only collected for one season.
More individualised estimates of hospitalisation costs
may be obtained with patient characteristics such as ges-
tational age and presence of BPD.
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Available resources are very for this research is limited,
hence the need to be cost conscious. OBJECTIVES: The
purpose of the research was to know which of the two
antitubercular drugs (both of which are still actively used
in Nigeria) is more cost effective in phase I treatment 
of tuberculosis and to inﬂuence decision making.
METHOD: Cost Effectiveness Analysis was the applied
tool for these methods, and the prescribed/dispensed anti-
tubercular drugs between 1997 and 1999 were reviewed
retrospectively. Relevant information such as diagnosis,
prescribed/dispensed drugs, dosage, duration of therapy,
physician’s remarks, and cost were obtained from patient
case notes and dispensed prescriptions. These were used
in conjunction with time and motion studies and standard
cost accounting technique. The cost per deﬁned daily
dosage (DDD) was calculated, and the costs of drug/
disposables acquisition and overhead costs were included
in the analysis. The literature was reviewed for positive
and negative consequences of the considered options.
Outcome measure of effectiveness was improved in signs
and symptoms of tuberculosis/eradication of Mycobac-
terium. A decision table was used to arrive at the effec-
tiveness rating, which was compared using chi sqaure
analysis. RESULTS: The analysis showed that ethambu-
tol tab is more cost effective than streptomycin inj, which
is still widely in use. The cost/DDD of ethambutol was
N4.00/unit effectiveness while that of Streptomycin was
N65.00/unit of effectiveness. The decision did not change
when some variables were altered in favour of strepto-
mycin inj. (the less cost effective option). Increasing the
cost of ethambutol by several folds, increased the effec-
tiveness rating of streptomycin to that of ethambutol etc.,
which did not change the conclusion. CONCLUSION:
Streptomycin inj. should no longer be considered as a
primary drug in the treatment of tuberculosis, which is
still very common in Nigeria. However, the various con-
traindications/side effects of ethambutol such as optic
neuritis need to be monitored for in patient. Economic
evaluation of therapy is necessary to avoid trading-off of
more cost effective therapeutic options.
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The use of economic analysis is increasingly advocated by
funding agencies to acheive efﬁcient cost containment
strategy. OBJECTIVES: To inform the use of antibacteri-
als in chosen hospitals and to propose inclusion of eco-
nomic evaluation of drug therapy in policy formulation
and decision-making. METHODS: Cost Minimisation
Analysis; the most applicable tool for generic equivalent
drugs was used. This was compared in three health insti-
tutions. These include a tertiary, Lagos University Teach-
ing Hospital (LUTH); a secondary, General Hospital
Lagos (GHL); and a primary, Health Centre Harvey
Road, Yaba (HCHR), as well as a community pharmacy
outlet for prescriptions of GHL. Relevant information
such as diagnosis, cost of drugs, dosage, duration of
therapy among others were obtained from patient case
notes for which antibacterials are the mainstay of therapy
and dispensed prescriptions. The mean cost per deﬁned
daily dosage (DDD) of generic and branded for each
antibacterial was computed for the various hospitals.
These were compared using student ‘t’ test. The outcome
measure was erradication of bacterial in question by the
respective antibacterials. RESULTS: The use of more
expensive branded drugs is very rampant even when the
generic equivalence is available. The difference in their
cost/DDD is very signiﬁcant (P < 0.05; n = 1,576 in
LUTH, n = 1,200 in GHL, n = 900 in HCHR, n = 750
in the community pharmacy). For example, in LUTH, 
the cost/DDD of ciproﬂoxacin was N310 for branded
product and N160 for generic. Also observed were some
irrational combinations especially in the primary health
centre. CONCLUSION: A form of economic evaluation
of drug therapy is necessary for health policy and deci-
sion makers to be more informed on cost implication 
of their choices and trade-offs. Systematic appraisal of
available options needs to be well understood in view of
limited resources. Appropriate and timely intervention 
for sustainable improvement is mandatory for costs to be
greatly minimised.
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OBJECTIVES: To evaluate the impact of an inﬂuenza
vaccination campaign: decrease of attack rates of
